MOESM2 of Comparison of efficacy and safety among axitinib, sunitinib, and sorafenib as neoadjuvant therapy for renal cell carcinoma: a retrospective study

Additional file 2: Table S1. Clinicopathological characteristics and tumor responses of patients with renal cell carcinoma receiving neoadjuvant therapy.